Fremont, CA., June 16, 2005 — Quark Biotech, Inc. announced this week findings from a study that outline the role of the hypoxia inducible gene RTP801 in cigarette smoking-induced pulmonary injury/inflammation at the annual Aspen Lung Conference in Aspen, Colorado from June 13th-17th, 2005. Dr. Rubin M. Tuder, Associate Professor of Pathology and Director of Cardiopulmonary […]
Fremont, CA (April 28, 2005) — Quark Biotech, Inc. announced today findings from a study that suggest that the hypoxia inducible gene RTP801 may serve an important role in the pathogenesis of early diabetic retinal disease. The study reveals that the knockout of RTP801 ameliorates diabetes-induced retinal vascular permeability (RVP) and electroretinogram (ERG) abnormalities in […]
Fremont, CA – March 03, 2005 – Quark Biotech, Inc. (QBI) announced today that it has been granted a Notice of Allowance from the United States Patent and Trademark Office for a patent titled, “p53 inhibitors and therapeutic use of the same.” Assigned to the University of Illinois at Chicago, this patent is exclusively licensed […]
Fremont, CA (February 28, 2005) – Quark Biotech, Inc. announced today that the Company has discovered the role of Ero-1L alpha gene in protein secretion under hypoxic conditions. This suggests that inhibition of Ero-1L alpha may have therapeutic applications in cancer and other pathologies involving hypoxia, a condition of reduced oxygen supply to tissues. Ero-1L […]
Fremont, CA and Negoya, Japan (February 8, 2005) – Sanwa Kagaku Kenkyusho Co., Ltd and Quark Biotech Inc. announce today that the companies have entered into an agreement for Quark to license the phase II compound BT16 to Sanwa for the treatment of dyslipidemia. The license provides Sanwa with exclusive development, manufacturing and marketing rights […]